The potential efficacy of influenza vaccines in prevention from cardiovascular complications of COVID-19
Social Determinants of Health,
Vol. 6 (2020),
14 July 2020
,
Page e20
https://doi.org/10.22037/sdh.v6i1.34771
Abstract
Cardiovascular complications of COVID-19 are not as common as pulmonary complications, while they could be life-threatening. Also, because there is no prevention strategy with appropriate safety and efficacy for these complications, researchers and clinicians are recommended to evaluate different strategies. Effects of influenza vaccines on reducing inflammatory responses and robust immune system, as well as decreasing probability of SARS-CoV-2/influenza co-infection make it a strategy for prevention from cardiovascular events in patients with COVID-19. We suggest further preclinical and clinical researches be conducted to determine the efficacy of influenza vaccines in the reduction of cardiovascular complications in patients with COVID-19 (10).
- Cardiovascular Syatem
- COVID-19
- Influenza Vaccines
- SARS-CoV-2
How to Cite
References
Lipsitch M, Swerdlow DL, Finelli L. Defining the Epidemiology of Covid-19 — Studies Needed. New England Journal of Medicine. 2020;382(13):1194-6.
Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. Nature Medicine. 2020;26(7):1017-32.
Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nature Reviews Cardiology. 2020;17(9):543-58.
Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiology. 2020;5(7):802-10.
Estabragh ZR, Mamas MA. The cardiovascular manifestations of influenza: A systematic review. International Journal of Cardiology. 2013;167(6):2397-403.
Madjid M, Naghavi M, Litovsky S, Casscells SW. Influenza and Cardiovascular Disease. Circulation. 2003;108(22):2730-6.
Zangiabadian M, Nejadghaderi SA, Mirsaeidi M, Hajikhani B, Goudarzi M, Goudarzi H, et al. Protective effect of influenza vaccination on cardiovascular diseases: a systematic review and meta-analysis. Scientific Reports. 2020;10(1):20656.
Lanthier PA, Huston GE, Moquin A, Eaton SM, Szaba FM, Kummer LW, et al. Live attenuated influenza vaccine (LAIV) impacts innate and adaptive immune responses. Vaccine. 2011;29(44):7849-56.
Ma S, Lai X, Chen Z, Tu S, Qin K. Clinical characteristics of critically ill patients co-infected with SARS-CoV-2 and the influenza virus in Wuhan, China. International Journal of Infectious Diseases. 2020;96:683-7.
Behrouzi B, Araujo Campoverde MV, Liang K, Talbot HK, Bogoch II, McGeer A, et al. Influenza Vaccination to Reduce Cardiovascular Morbidity and Mortality in Patients With COVID-19: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2020;76(15):1777-94.
- Abstract Viewed: 127 times
- PDF Downloaded: 130 times